CD274 and Obesity: Three ICOS‐specific agonistic mAbs are currently used alone or in combination with anti‐PD‐L1 to treat advanced solid tumors including NSCLC.36, 37 However, none of the described approaches have explored the correlation between ICOS and obesity.